#USA #Wilmington #Drug Development #DeepCyte #AI toxicology

DeepCyte Secures $1.5M to Advance AI in Toxicology

DeepCyte, an innovative techbio company specializing in artificial intelligence for toxicology within drug development, announced its official launch today, backed by $1.5 million in seed funding. This funding marks a significant step in the company's mission to bring efficiency and precision to the biopharmaceutical industry by enhancing the prediction and explanation of drug toxicity at the single-cell level.

The Challenge of Drug Toxicity

Drug toxicity is a leading culprit for failures in clinical trials and the subsequent withdrawal of drugs from the market, which costs the pharmaceutical industry billions of dollars annually. Traditional testing methods, such as animal models and bulk assays, often fall short in predicting human responses accurately. These methods struggle to account for the heterogeneous cellular effects responsible for adverse outcomes.

In light of evolving regulatory standards, there is an urgent need to adopt human-relevant and evidence-based testing methods. Agencies like the FDA and EMA are increasingly demanding innovative predictive technologies that can meet these criteria.

Introducing DeepCyte's Innovative Solutions

DeepCyte's two primary offerings aim to address these challenges effectively. The first is MetaCore, a high-throughput platform for single-cell metabolomics. This groundbreaking technology utilizes laser-based sampling and mass spectrometry to deliver comprehensive molecular profiles, enabling insights into cellular activity and capturing variations in responses that bulk analysis often misses. By generating large datasets that are optimal for AI applications, MetaCore minimizes sample preparation and costs significantly, paving the way for broader adoption in biopharma.

The second solution, DeeImmuno, is powered by MetaCore data and harnesses advanced machine learning techniques explicitly designed to utilize single-cell biology insights. Trained on proprietary single-cell metabolomics atlases, DeeImmuno predicts the toxicity class of compounds, identifies key biomarkers, and elucidates the molecular mechanisms responsible for toxicity. In evaluations involving a cohort of 100 withheld drugs, DeeImmuno achieved an impressive accuracy rate of 94% in predicting detailed toxicity mechanisms — a feat that surpasses the capabilities of conventional methodologies.

Leadership and Future Vision

At the helm of DeepCyte is CEO Theodore Alexandrov, Ph.D., who has an extensive background in pharmacology and biotechnology. He previously developed METASPACE, a cloud software platform widely utilized by researchers, and co-founded SCiLS GmbH, which was later acquired by Bruker. Alongside Alexandrov, the company’s leadership team comprises experts in AI and life sciences commercialization, positioning DeepCyte as a forward-thinking leader in toxicology.

The seed funding round was significantly supported by Carl J. G. Evertsz, a renowned medtech executive, former CEO, and investor, who will take on the role of Board Chair. With headquarters situated in both Delaware and Copenhagen, DeepCyte is determined to redefine toxicology standards and advance drug safety testing to be more human-centric.

Conclusion

As DeepCyte embarks on this journey, it aims to not only enhance drug safety testing procedures but also to eliminate the reliance on outdated testing methodologies. The innovative solutions offered by DeepCyte represent a critical shift towards improved patient safety and more effective drug development practices in the biopharmaceutical landscape. With AI technology at its core, DeepCyte is poised to make significant contributions to the future of drug development and patient care.